Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that on Monday 8th and Tuesday 9th May 2017, Professor Chris Nutting, Non-Executive Director of the Company, purchased a total of 202,500 ordinary shares of 25 pence in the Company at an average price of 24.67 pence per Ordinary Share.
Following these transactions, Professor Nutting holds 217,316 Ordinary Shares, representing 0.29% of the Company’s share capital as enlarged by the issue of new Ordinary Shares notified on 8th May 2017.
|
Advanced Oncotherapy Plc |
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
Jonathan Senior / Ben Maddison |
Tel: +44 20 7710 7600 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |